The Sanford Project aims to cure T1D through the development of beta cell regeneration therapies (the cells which produce insulin in the pancreas).
Under the collaboration, DiaMedica is expected to be working with The Sanford Project associate scientist Alexei Savinov, who is a T1D beta cell regeneration and autoimmunity expert using the non-obese diabetic (NOD) mouse model.
Savinov is expected to be performing a definitive study in the NOD mouse using DM-199.
The study is designed to measure the dual actions of DM-199, which are to protect/regenerate beta cells and to halt the autoimmune attack.
DiaMedica CEO Rick Pauls said that DiaMedica is delighted to be working with Savinov and The Sanford Project.
"This collaboration will provide additional external validation of DM-199 by working with the T1D research group at the Sanford Project," Pauls said.
"We believe DM-199 has the potential to protect/proliferate beta cells and halt autoimmune attacks which may result in a promising treatment for type I diabetes patients."